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Alzheimer's disease (AD) is a neurodegenerative disease that leads to the progressive deterioration of cognitive
and memory functions. The deposition of extracellular beta-amyloid (Aβ) senile plaques and intracellular tau
neuroﬁbrillary tangles are considered the cardinal pathological hallmarks of AD, however, accumulating evi-
dence indicates that immune cells may also play an important role in disease pathogenesis. Among these im-
mune cells, blood-derived cells and their inﬁltration into the CNS towards Aβ plaques have been implicated in
therapeutic strategies against AD. Here, we review the current literature on blood cell migration into the AD
brain and the important players involved in this selective migration towards Aβ plaques.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. AD pathology and β-amyloid plaques
Alzheimer's disease (AD) is characterized by the presence of extra-
cellular senile beta-amyloid (Aβ) plaques and intracellular neuroﬁbril-
lary tau tangles, however, other disease pathology features include the
loss of cholinergic neurons and synapses, the loss of white matter,
congophilic/cerebral amyloid angiopathy (CAA), inﬂammation, oxida-
tive stress and cerebrovascular dysfunction (Mufson et al., 2008; Perl,
2010; Querfurth and LaFerla, 2010; Serrano-Pozo et al., 2011). Senile
plaques are primarily composed of Aβ peptides, byproducts of amyloid
precursor protein (APP) metabolism following its sequential cleavage
by the enzymes β- and γ-secretase, which results in the generation of
two Aβ species: Aβ40 and Aβ42 (LaFerla et al., 2007). Aβ40 is the more
prevalent isoform found in vivo and serves as a major component of
CAA (LaFerla et al., 2007; Serrano-Pozo et al., 2011). Aβ42 makes up
only 10% of the total Aβ, but is the more predominant toxic species
found in plaques due to its enhanced hydrophobicity, aggregation and
ﬁbrillization potential. It can spontaneously self-aggregate to generate
soluble neurotoxic oligomers or insoluble ﬁbrils that form plaques
(LaFerla et al., 2007; Querfurth and LaFerla, 2010). Neuritic or dense-
core senile plaques contain Aβ ﬁbrils arranged radially into a central
core. More importantly, these plaques are typically surrounded by dys-
trophic neurites, reactive astrocytes, activated microglial cells, and syn-
aptic loss, indicating that these cells may play an important role in
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disease pathology (Fig. 1A). Abnormal mitochondria and lysosomes
have also been foundwithin these activated cells, indicating that energy
or protein degradation processes may be compromised. In addition,
there is also evidence that Aβ plaques are directly associated with
brain vessels, indicating that blood vessel proximity may play a role in
plaque formation and/or remodeling (Kumar-Singh et al., 2005).
2. Inﬂammatory processes around β-amyloid plaques in AD
In AD brains, Aβ plaques are surrounded by activatedmicroglial cells
and reactive astrocytes. In addition, several inﬂammation-relatedmedi-
ators have been foundwithin plaques. Microglia are considered the res-
ident macrophages of the CNS and serve as important players in driving
Fig. 1. Themigration of peripheral monocytes to beta-amyloid (Aβ) plaques in the AD brain. (A) A schematic rendering of ﬂuorescent stainings (taken from our own laboratory) of an Aβ
plaquewith associated brain vessels. The Aβ core contains aggregated Aβ peptides, surrounded by reactive astrocytes and activatedmicroglia. Monocytes migrate into the brain andmay
differentiate into macrophages or microglia. (B) A hypothetical rendering of monocyte recruitment into the AD brain. The recruitment of monocytes into the AD brain begins when Aβ
deposition and associated neuronal damage triggers a local immune response activating astrocytes, endothelial cells, andmicroglia. This activation leads to the secretion of the chemokine
CCL2,which recruitsmore immune effector cells (mainly CCR2+monocytes) to the site of parenchymal Aβ deposition. Residentmicroglia appear to lose their ability to effectively phago-
cytose Aβ, however, blood-derived monocytes differentiate into macrophages, which are more effective at phagocytosis and clearing Aβ plaques. Although CCR2+ inﬂammatory mono-
cytes have become the primary monocyte subpopulation implicated in providing therapeutic beneﬁts to the AD brain, recent data indicates that CX3CR1hi resident monocytes may be
responsible for clearing vascular Aβ deposition.
This cartoon B has been partly adapted andmodiﬁed from others: Britschgi andWyss-Coray (2007), El Khoury and Luster (2008), Gate et al. (2010), Hickman and El Khoury (2010), Malm
et al. (2010), Michaud et al. (2013), Mildner et al. (2011).
9L.A. Hohsﬁeld, C. Humpel / Experimental Gerontology 65 (2015) 8–15
the inﬂammatory response in AD (Wyss-Coray and Rogers, 2012). How-
ever, they also prove vital in promoting and maintaining a healthy CNS
(Schwartz and Shechter, 2010). Using their highlymotile processes they
constantly sample and survey their surrounding microenvironment
making them the ﬁrst line of defense against pathogens and injury in
the brain (Glass et al., 2010; Wyss-Coray and Rogers, 2012). Without
physiological stress, microglia display a ramiﬁed or deactivated pheno-
type secreting anti-inﬂammatory and neurotrophic factors (Glass et al.,
2010; Khandelwal et al., 2011). Histological studies have shown that ac-
tivated (amoeboid) microglia surround senile plaques in AD brains,
alongwith astrocytes, and that these cells stain positive for inﬂammato-
ry markers including major histocompatibility complex (MHC) class II,
cyclooxygenase (COX)-2, monocyte chemoattractant/chemotactic pro-
tein (MCP)-1, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, or
IL-16 (Akiyama et al., 2000; Glass et al., 2010). However, the role of
these cells is somewhat complex. On one side, data indicates that mi-
croglia are poor phagocytes of Aβ and thus cannot play a signiﬁcant
role in Aβ clearance or plaque remodeling, either promoting or
protecting against Aβ-induced pathology (Gate et al., 2010; Grathwohl
et al., 2009). On the other side, reports indicate that microglial cells
are capable of remodeling and enhancing the clearance of Aβ plaques
(Chakrabarty et al., 2010; Gate et al., 2010; Kiyota et al., 2009). Despite
these ﬁndings, it is becoming more accepted that microglia activation
(and the release of neurotoxic factors) is a secondary event following
Aβ deposition and aggregation (Schwartz and Shechter, 2010).
3. The migration of blood cells into the CNS
The brain employs several immune control mechanisms to tightly
regulate inﬂammation and its potential brain damage-promoting path-
ways (Rezai-Zadeh et al., 2009). One important feature of this immune
privilege involves the blood–brain barrier (BBB),which in the context of
inﬂammation, is responsible for restricting the entry of substrates and
cells into the brain (Rezai-Zadeh et al., 2009). During an effective im-
mune response, vascular permeability is increased along with blood
ﬂow to the site of inﬂammation or injury. This is accompanied by the se-
lective entry of immune cells from the periphery, which help further
propagate an inﬂammatory response by producing cytokines and carry-
ing out other important effector cell functions (Yong and Rivest, 2009).
Migration from the blood into the brain occurs at post capillary venules
and involves amultiple-step process of events that aremediated by var-
ious chemokines, their associated receptors and adhesion molecules.
Peripheral immune cell migration into the CNS resembles typical
leukocyte extravasation into other organs. There are four ‘classic’ steps
of immune cell extravasation including: 1) capture (tethering) and
rolling, which involves the interaction of selectins and mucins and/or
integrins and IgG members; 2) activation, which is propagated by
chemokines leading to integrin activation; 3) arrest, which is mediated
through integrins and their counter-ligands; and 4) diapedesis or trans-
migration (Rossi et al., 2011). First, immune cells roll along the endothe-
lium. This is initiated by selectin binding resulting in the ‘tethering’ of
the immune cell to the endothelium (this involves e.g., P-selectin and
very late antigen-4 (VLA-4)) (Malm et al., 2010). Interestingly, a subset
of immune cells also patrols the resting endothelium circulating against
the direction of blood ﬂow; dependent on the interaction of a speciﬁc
integrin, e.g., the chemokine receptor CX3CR1 (Prinz et al., 2011).
During the process of rolling and tethering, engagement with a
chemoattractant can lead to integrin activation on the immune cells
and increased afﬁnity of the integrin for its associated adhesion mole-
cule on the endothelium. This ultimately leads to immune cell adhesion.
Following adhesion, the immune cell undergoes transendothelial mi-
gration or extravasation from the blood vessel. These early transmigra-
tion events involve e.g., platelet endothelial cell adhesion molecule
(PECAM-1), a cell adhesion molecule expressed on endothelial cells,
and e.g., RAGE, which is a receptor for macrophage 1 (MAC-1; CD11b)
(Malm et al., 2010). Once across the endothelium and basement
membrane, the immune cell crosses the perivascular space and glia
limitans and migrates towards the source of the chemoattractant
(i.e., the site of inﬂammation). In vitro studies have demonstrated that
Aβ promotes the expression of adhesion molecules and can enhance
immune cell adhesion and subsequent transmigration across the BBB.
3.1. Red blood cells in the AD brain
Although alterations have been found in red blood cells isolated
fromADpatients (Blass et al., 1985; Cortes-Canteli et al., 2012;Mohanty
et al., 2010; Sabolovic et al., 1997; Zhang et al., 2013), there is no indica-
tion that these cells inﬁltrate the AD brain nor that such inﬁltration
plays a role in disease progression. It could, however, be possible that
these cells affect leukocyte inﬁltration into the CNS. In AD, red blood
cells showmembrane alterations aswell as impairments in their oxygen
delivery capabilities (Mohanty et al., 2010),which could result in aggra-
vating oxidative stress and vascular injury, ultimately leading to en-
hanced endothelial permeability and the inﬁltration of peripheral
immune cells.
3.2. Platelets in the AD brain
Platelets are responsible for maintaining the integrity of blood ves-
sels and promoting hemostasis. These cells are of particular interest in
AD since they contain high amounts of APP and release Aβ40 into the
blood stream (Evin et al., 2003). Furthermore, studies have shown
that the larger 130 kDa APP isoform is signiﬁcantly reduced in platelets
isolated from AD patients, implicating their potential role in altered APP
metabolism (or use in the development of AD biomarkers) (Padovani
et al., 2001). Vascular injury or stimulation via Aβ could result in platelet
activation and adhesion to the vessel wall. These studies along with
others provide increasing evidence that platelet activation contributes
to CAA. In this context, activated platelets in turn could produce more
Aβ as well as chemokines (Zhang et al., 2013), promoting immune cell
inﬁltration. In fact, platelets are known ampliﬁers of leukocyte adhesion
(von Hundelshausen et al., 2009). A recent study by Thornton and col-
leagues demonstrated that platelets secrete IL-1α, which drives the
transendothelial migration of neutrophils in vitro (Thornton et al.,
2010). However, thus far there have been no indications that platelets
migrate into the AD brain (Kniewallner et al., 2015).
3.3. Leukocytes in the AD brain
Leukocytes are considered the immune cells of the periphery and
can be divided into granulocytes including basophils (b1%), eosinophils
(b6%), and neutrophils (40–75%), and lymphocytes (20–45%) including
T cells, B cells, and natural killer cells andmonocytes (2–10%). Although
the AD brain does not present prominent inﬁltration of peripheral
leukocytes such as those seen in other neuroinﬂammatory diseases
(e.g., multiple sclerosis), recent studies indicate that their inﬁltration
does occur and is stimulated by Aβ (Rezai-Zadeh et al., 2009). For in-
stance, early investigationsdemonstrated that Aβ infusion in rats results
in the adhesion andmigration of leukocytes across arteries, venules and
cerebral vessels (Rossi et al., 2011). However, whether this inﬁltration
does indeed occur in AD and by which particular cell type, remain
under intense debate.
3.3.1. Granulocytes
Neutrophils are themost abundant population of cells in the periph-
eral blood accounting for 40–75% of leukocytes in human blood. These
cells specialize in phagocytosis, rapidly mobilizing to areas of infection
and known for their ability to work in anaerobic conditions. However,
the lifespan and functional role of neutrophils during an innate immune
response is relatively short-lived, compared to macrophages, which
help propagate and sustain a local response. Neutrophil inﬁltration
into the CNS has been implicated in CNS diseases involving an
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inﬂammatory reaction (e.g., bacterial meningitis) (Ransohoff and
Brown, 2012), however, whether this migration takes place under
chronic neuroinﬂammatory conditions (e.g., multiple sclerosis and
AD) remains unknown. In AD, one recent study reports that Ly6C/G
(Gr-1)+ (a marker for cells of the myeloid lineage) cells migrate to-
wards Aβ plaques in an AD disease mouse model. Using 2-photon mi-
croscopy the authors observed dynamic extravasation of these cells
from blood vessels into the brain parenchyma of 9- to 13-month-old
5XFAD mice (Baik et al., 2014). Although the underlying mechanism
for this migration is still unclear, data from these experiments indicates
that Aβ plaques, but not soluble Aβ, may play an important role in
recruiting these cells from the blood. A previous study in neutrophils
has shown that serpin-enzyme complex (SEC) receptor mediates the
chemotaxis of these cells in response to the Aβ25–35 peptide (Joslin
et al., 1992). Thus, it could be possible that depending on the species
of Aβ, different inﬂammatory responses (i.e., an early and short pro-
inﬂammatory burst response vs. a low and chronic response) may be
generated based on the activation of speciﬁc receptors and pathways.
However, a more detailed discussion of this issue can be found in the
monocyte section.
3.3.2. Lymphocytes
Although peripheral lymphocyte migration is a not prominent fea-
ture in the ADbrain like other neurodegenerative diseases (i.e., multiple
sclerosis), T cell inﬁltration has been observed in the brains of AD pa-
tients (Itagaki et al., 1988; Rogers et al., 1988; Togo et al., 2002; Town
et al., 2005), albeit at low numbers (Lucin and Wyss-Coray, 2009;
Rossi et al., 2011). In addition to the brain parenchyma, alterations in
T cells have been detected in the periphery of AD patients (Larbi et al.,
2009; Monsonego et al., 2003, 2006) and CD4+ and CD8+ T cells
have been found associated with CAA pathology, in addition to mono-
cytes and macrophages in leptomeningeal and cortical vessels
(Yamada et al., 1996). Previous investigations have shown that periph-
eral T cells in AD patients overexpress chemokines and receptors (i.e.,
MIP-1α and CXCR2) associated with T cell migration across the endo-
thelium (Liu et al., 2010; Man et al., 2007). Furthermore, hippocampal
Aβ injection in the rat results in the upregulation of receptors (i.e.,
RAGE, CCR5) involved in promoting T cell migration into the brain (Li
et al., 2009).
Despite these ﬁndings, it still remains unclear how T cells enter the
brain through the BBB and what speciﬁc stimulus is responsible for T
cell accumulation in the AD brain (Monsonego et al., 2006, 2013; Rossi
et al., 2011). Recent in vitro studies suggest that Aβ1–42-treated microg-
lia release TNF-α to promote transendothelial migration of T cells via
MHC I expression (Yang et al., 2013). In addition, studies involving Aβ
immunization have indicated that CD11c+ dendritic cells may stimu-
late Aβ-speciﬁc T cells to target Aβ depositions in the brain (Fisher
et al., 2014). Speciﬁc cytokines may also play an important role in T
cell inﬁltration. A previous study by Buckwalter and colleagues showed
that local expression of TGF-β1 increases bothmeningeal and parenchy-
mal T cell number in a mouse model of AD following Aβ1–42 immuniza-
tion (Buckwalter et al., 2006).
It also remains unclear what role these cells play in disease patholo-
gy and cognitive outcome. Previous studies indicate that T cells in the
CNS can both promote and impair cognitive processes based on their
given subtype (Estes and McAllister, 2014). Speciﬁcally, recent prelimi-
nary data indicates that transferring Aβ-speciﬁc Th1 cells enhances Aβ
plaque development in APP-swe/PS1dE9 mice, whereas transferring
Aβ-speciﬁc Th2 cells has no effect. Interestingly, the transfer of Th17
cells reduces Aβ concentrations in the hippocampus (Lynch and Mills,
2012). In another study, systemic transplantation of T regulatory cells
ameliorates cognitive impairment and reduces Aβ plaque deposition
and soluble Aβ levels. This treatment also resulted in a reduction in
microglial activation and systemic inﬂammatory factors (Yang et al.,
2013). Although not characterized from the periphery, a recent study
showed that intracerebroventricular-injected Th1 CD4+ T cells are
able to migrate within the brain parenchyma associated with increased
expression of ICAM-1 and MHC II. This study also shows that these T
cells effectively target Aβ plaques, increase Aβ uptake and promote
neurogenesis in a mouse model of AD (Fisher et al., 2014). In addition,
these authors have shown that T cell migration towards Aβ plaques
and signiﬁcant plaque clearance also occur in APP/IFN-γ double trans-
genic mice following Aβ immunization (Fisher et al., 2010). However,
in both transgenic mice and AD patients this Aβ immunization results
in meningoencephalitis (Buckwalter et al., 2006; Fisher et al., 2014).
3.3.3. Monocytes
Monocytes represent 2–10% of peripheral blood leukocytes in
humans and rodents. They are generated from myeloid precursor cells
in the bone marrow and released into the bloodstream where they cir-
culate before entering organs and differentiating into tissue-speciﬁc
macrophages and dendritic cells (Ziegler-Heitbrock, 2007). Monocytes
are characterized morphologically as mononuclear cells with bean-
shaped nuclei and phenotypically by their expression of surface
markers. There are a wide variety of phenotypically and functionally
heterogeneous monocyte subpopulations varying in maturation, differ-
entiation, and activation states based on their differential expression of
these surfacemarkers (Auffray et al., 2009; Buckner et al., 2011; Shi and
Pamer, 2011).
In humans, monocytes are identiﬁed by their expression of CD14
and CD11b and further characterized into heterogeneous subsets by
their differential expression of CD14 and CD16. Mouse monocytes are
deﬁned by their expression of CD11b (membrane-activating complex
1 (Mac-1)), CD115 (M-CSF receptor), and F4/80 (Strauss-Ayali et al.,
2007). In both humans and rodents, there are twomain subpopulations
that dividemonocytes phenotypically and functionally: ‘classical' or ‘in-
ﬂammatory’ monocytes (Ly6C+ in mice), which express higher levels
of CCR2, and ‘non-classical' or ‘resident’ monocytes (Ly6C- in mice),
which express higher levels of CX3 chemokine receptor 1 (CX3CR1;
fractalkine) (Yrlid et al., 2006). Michaud et al. (2013) recently showed
in mice that patrolling (Ly6Clo) monocytes are attracted to the walls of
Aβ-positive veins. Although more functional studies are needed to
help distinguish their distinct functional and physiological roles, recent
studies in rodent models have concluded that CCR2-expressing mono-
cytes are recruited to sites of inﬂamed or injured tissue, whereas
CX3CR1-expressing cells exhibit more patrolling behavior and involve-
ment in tissue maintenance (Gordon and Taylor, 2005; Strauss-Ayali
et al., 2007).
Monocytes play an important role during innate and adaptive im-
mune responses (Tacke and Randolph, 2006; Ziegler-Heitbrock, 2007).
Inﬂammation and other injury lead to an increased recruitment of
monocytes to peripheral tissues aiding in host immune system defense
and repair. During an inﬂammatory response, monocytes are recruited
to the sites of inﬂammation by CCL2 (classical monocytes) or CX3 che-
mokine ligand 1 (CX3CL1; resident monocytes) and subsequently dif-
ferentiate into effector cells (Ziegler-Heitbrock, 2007). Depending on
their surface marker expression, monocytes can further propagate the
immune response by secreting inﬂammatory mediators including cyto-
kines and chemokines (proinﬂammatory monocytes), by giving rise to
antigen-presenting cells including macrophages and dendritic cells, or
by performing antigen-presenting cell activity themselves (i.e., tissue
repair and phagocytosis) (Khandelwal et al., 2011).
3.4. Monocyte-derived neurotoxicity
The role of monocytes and monocyte-derived cells in the propaga-
tion of neurodegenerative disease is still under intense debate. Similar
to microglia, these cells may induce beneﬁcial effects, but also contrib-
ute to neurodegeneration through uncontrolled inﬂammation and/or
neurotoxic pathways. Previous studies have shown that microglia and
THP-1 monocytes can interact with ﬁbrillar Aβ and stimulate the pro-
duction of proinﬂammatory cytokines, reactive oxygen species (ROS),
11L.A. Hohsﬁeld, C. Humpel / Experimental Gerontology 65 (2015) 8–15
and neurotoxic secretory molecules, ultimately resulting in neuronal
apoptosis (Combs et al., 2001). Speciﬁcally, studies have demonstrated
that CD36, a class B scavenger receptor, CD47, an integrin-associated
protein, and α6β1-integrin form a cell surface receptor complex that
mediates the binding of microglia or THP-1 monocytes to Aβ ﬁbrils.
This binding subsequently activates a tyrosine kinase intracellular
signaling cascade stimulating IL-1β, TNF-α and ROS production
(Bamberger et al., 2003). In line with these studies, El Khoury and col-
leagues have also shown that CD36 canmediate the response ofmicrog-
lia and macrophages to Aβ, including promoting the secretion of H2O2,
cytokines, chemokines and ROS (Coraci et al., 2002; El Khoury et al.,
2003). In addition to CD36, recent investigations have also identiﬁed
the NOD-like receptor family, pyrin domain containing 3 (NLRP3)
inﬂammasome as an important mediator of microglia/monocyte-
induced neurotoxicity. These studies have demonstrated that ﬁbrillar
Aβ can act as an activator of inﬂammasomes, which promotes
caspase-1 signaling and the subsequent release of IL-1β, IL-18, IL-1α
proinﬂammatory cytokines (Sheedy et al., 2013). Converging evidence
indicates that phagocytosis of Aβ (through the interaction of CD36
and a TLR heterodimer of TLR4-TLR6) and subsequent loss of lysosome
integrity, triggered by aggregated or insoluble material, result in the re-
lease of lysosomal content (e.g., cathepsin B and/or ROS) and assembly
of the inﬂammasome (Halle et al., 2008; Sheedy et al., 2013). Thus, it ap-
pears that the engulfment and endocytosis of Aβ by macrophages re-
sults in the conversion of soluble Aβ into its more ﬁbrillar or
pathogenic form, ultimately triggering dysfunctional degradation/lyso-
some damage and activating the inﬂammasome and release of
proinﬂammatory and neurotoxic molecules (Sheedy et al., 2013). Inter-
estingly, a recent study by Heneka and colleagues has shown that a de-
ﬁciency in theNLRP3 inﬂammasome results in the skewing ofmicroglial
cells towards amoreM2or anti-inﬂammatory phenotype, as well as, at-
tenuates amyloid accumulation in an AD mouse model (Heneka et al.,
2013). Together, these studies indicate that microglia and monocyte-
derived cells also play an important role in promoting proinﬂammatory
and neurotoxic pathways. Thus, developing strategies against chronic
monocyte/microglial cell inﬂammatory activation may prove beneﬁcial
for AD neurodegeneration. In support of this, recent investigations have
shown that the use of peroxisome proliferator-activated receptor γ
(PPARγ) agonists, which suppress inﬂammatory gene expression, ame-
liorate spatialmemory performance in an ADmousemodel. The authors
report that treatment of a PPARγ agonist results in the enhanced phago-
cytosis of Aβ by microglial cells (mediated by increased CD36 expres-
sion) as well as the reduction of cortical and hippocampal Aβ levels
(Yamanaka et al., 2012).
3.5. Implications for monocyte-derived recruitment, phagocytosis and
therapeutic use in AD
Emerging evidence from studies in stroke, brain trauma, and AD in-
dicate that these severe brain disorders can lead to BBB breakdown and
subsequent migration of blood-derived monocytes into the CNS (Malm
et al., 2010). Interestingly, post-mortem brain sections of AD patients
with co-morbid stroke exhibit deposition of brain-inﬁltrating macro-
phages containing Aβ ﬁbrils (Wiesniewski et al., 1991; Akiyama et al.,
1996). Despite the detrimental role of leukocyte inﬁltration in some
neurological disorders, accumulating data indicates that peripheral
monocytes may be beneﬁcial to AD in ameliorating disease pathology
and progression.
One of the ﬁrst studies to demonstrate the beneﬁts of monocytic
cells was the investigation performed by Simard and colleagues in
mice, which showed that blood-derived microglia (now referred to as
bone marrow-derived/blood-derived monocytes or macrophages) are
recruited to sites of Aβ plaque deposition (triggered by Aβ40 and
Aβ42) and can eliminate Aβ deposits via phagocytosis (Simard et al.,
2006). Following this study, El Khoury et al. demonstrated that CCR2
deﬁciency, or disrupting the recruitment and accumulation of
mononuclear phagocytes (i.e., microglia/blood-derived monocytes) to
lesion sites, impairs the accumulation of these cells near Aβ plaques
and accelerates Aβ plaque burden in AD transgenic mice (El Khoury
et al., 2007). Together, these studies indicate that blood-derived mono-
cytes play an important neuroprotective role via Aβ clearance. In sup-
port of these ﬁndings, others have shown that stimulating the
inﬁltration or turnover of peripheral monocytic cells (e.g., blocking
immunosuppressive TGF-β or administrating M-CSF, granulocyte
colony-stimulating factor (G-CSF), granulocyte macrophage colony-
stimulating factor (GM-CSF), chitin, or LPS, or NGF) can attenuate AD
pathology (i.e., reducing parenchymal and cerebrovascular Aβ deposi-
tion) and cognitive deﬁcit in AD rodent models (Boissonneault et al.,
2009; Hawkes and McLaurin, 2009; Malm et al., 2010; Naert and
Rivest, 2013; Rezai-Zadeh et al., 2009; Town et al., 2008; Yong and
Rivest, 2009; Hohsﬁeld et al., 2014). In addition to eliminating Aβ de-
posits and preventing plaque formation, these cells (mainly the anti-
inﬂammatory subset) are also capable of arresting the local production
of proinﬂammatory factors (e.g., TNF), enhancing neurogenesis, releas-
ing proteolytic enzymes and proteinases, and producing reparative
growth factors (e.g., insulin-like growth factor I, IGF-I) (Gate et al.,
2010; Malm et al., 2010; Schwartz and Shechter, 2010).
However, there is still some controversy regarding monocyte inﬁl-
tration in the AD brain. Our lab and other researchers have provided
convincing in vitro data indicating that the transmigration ofmonocytes
into the CNS is a speciﬁc response to Aβ (Fiala et al., 1998; Giri et al.,
2000; Humpel, 2008; Malm et al., 2010). In support of these ﬁndings,
others have shown that this is also true in vivo. Lebson et al. recently re-
ported that signiﬁcantmonocyte deposition is present only in the brains
of AD transgenic mice, neighboring Aβ plaques, whereas little or no cell
deposition is present in the brains of control animals (Lebson et al.,
2010; Malm et al., 2005; Stalder et al., 2005). Unlike other studies,
which show monocyte inﬁltration following irradiation and bone-
marrow transplant, this study indicates that monocytes can inﬁltrate
the ADmouse brain without prior irradiation-related BBB damage. Fur-
thermore, Lampron and colleagues demonstrated that the formation of
Aβ plaques in an ADmouse model is sufﬁcient to induce bonemarrow-
derived cell entry into the CNS without irradiation, albeit at low num-
bers (Lampron et al., 2013).
In addition to chemokine receptors like CCR2, formylpeptide
receptors (FPRs) are also recognized as another group of classical
chemoattractant receptors involved in leukocyte trafﬁcking (Chen
et al., 2013). A previous investigation in human peripheral bloodmono-
cytes, demonstrated that chemotaxis towards Aβ and APP occurs via the
activation of formyl peptide receptor like-1 (FPRL1), a low afﬁnity re-
ceptor located on leukocytes and mononuclear phagocytes (Kaneider
et al., 2004). Interaction of FPRL1 or its mouse homolog FPR2 with Aβ
results in the internalization of Aβ by macrophages, enhanced chemo-
tactic activity, as well as the release of neurotoxic substances
(Iribarren et al., 2005).
Extensive evidence indicates that CCL2 and CX3CL1 play an impor-
tant role in monocyte trafﬁcking during inﬂammatory disorders includ-
ing AD (Hickman and El Khoury, 2010). Some hypothesize that the
CCL2/CCR2 pathway is involved in monocytic trafﬁcking out of the
bone marrow and into the blood, while the CX3CL1/CX3CR1 pathway
is involved in the capture and adhesion of monocytes to the vessel
wall near the barrier of the inﬂamed tissue (Hickman and El Khoury,
2010). Thus, it could be possible that FPRs may play a distinct role in
local monocyte or mononuclear phagocyte recruitment, in which cells
from the perivascular space or non-lesioned parenchyma (where Aβ
deposition is not apparent) are recruited to areas of the parenchyma
where senile plaques and Aβ accumulation are prevalent.
Extensive in vivo and in vitro evidence indicates that blood-derived
monocytes can phagocytose Aβ (Hawkes and McLaurin, 2009; Malm
et al., 2010; Town et al., 2008), however, the exact mechanism of how
monocytes clear Aβ remains unclear. As previously mentioned, several
studies have demonstrated that insoluble ﬁbrillar Aβ, the aggregated
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form of Aβ found in senile plaques, can bind to receptors on microglia
and activate these cells to produce cytokines, chemokines, and reactive
oxygen and nitrogen species. The receptors involved in promoting this
binding and/or phagocytosing ﬁbrillar Aβ include: class A1 scavenger
receptors (Scara1), class B2 scavenger receptors (Scara2), CD36, and
RAGE (Frenkel et al., 2013). Other microglial receptors involved in Aβ
uptake include TLR4/CD14, FPRL1, and complement receptors
(Sokolowski and Mandell, 2011). These cells also produce a number of
Aβ-degrading enzymes, including insulysin, neptrilysin, and others
(Frenkel et al., 2013). However, again whether these same receptors
and/or pathways are also involved in monocyte Aβ clearance remains
unclear. Furthermore, it is important to consider the varying forms of
Aβ and how these species stimulate differential activation of mononu-
clear phagocytes and their subsequent degradation of Aβ. Previous
studies indicate that soluble Aβ is taken up via pinocytosis, whereas ﬁ-
brillar Aβ is taken up by phagocytosis in macrophages/microglia
(Sokolowski and Mandell, 2011). A recent study by Frenkel and col-
leagues indicates that Scara1, a scavenger receptor found on myeloid
cells, serves as the main receptor for soluble Aβ clearance, rather than
CD36 (Frenkel et al., 2013). Recent genome-wide association studies
in AD patients have also identiﬁed a new susceptibility loci and possible
receptor for altered Aβ processing: TREM2, a receptor involved in regu-
lating phagocytosis and inﬂammatory responses in myeloid cells
(Hickman and El Khoury, 2014). Further studies are needed to distin-
guish which receptors and pathways distinguish successful phagocyto-
sis from ineffective phagocytosis and whether this is cell type
dependent (i.e., improved in monocytes vs. microglia) or Aβ species
dependent.
The question remains, however, if blood-derived monocytes are re-
cruited to the AD brain (either as a speciﬁc response to Aβ or a leaky
BBB caused by vascular injury) and are effective phagocytes of Aβ
(based on animal studies), thenwhydoes AD continue to progress? Fur-
thermore, could it be possible that AD patients suffer from faulty im-
mune signaling functions in respect to the inﬁltration, patrolling and/
or phagocytic (e.g., toll-like receptor, TLR) abilities of these monocytic
cells? To our knowledge, there have been no reports on the immune de-
fects seen in mouse AD macrophages, however, reports have shown
that the expression of receptors involved in Aβ uptake and Aβ-
degrading enzymes, does decrease with age in AD mouse models
(Frenkel et al., 2013). Thus, it could be possible that microglia and/or
monocyte-derived cells could become dysfunctional, lose their ability
to degrade Aβ, produce proinﬂammatory cytokines and neurotoxins,
which in turn promote further Aβ production and accumulation
(Hickman and El Khoury, 2014).
Clinical investigations have shown that peripheral monocytic cells
from AD patients appear ineffective at phagocytosing Aβ (altered TLR,
MHC II, or COX-2, CCR2) and may even contribute to CAA (Fiala et al.,
2007; Malm et al., 2010; Mildner et al., 2011; Zaghi et al., 2009). These
patient studies using monocytes isolated from healthy individuals
show that these cells can phagocytose and degrade Aβ as well as gain
access to Aβ-positive vessels and ingest Aβ. Monocytes from AD pa-
tients, on the other hand, are unable to phagocytose Aβ as well as dis-
play lower expression of surface proteins involved in Aβ phagocytosis
and pronounced apoptotic signaling (Fiala et al., 2005, 2007; Zaghi
et al., 2009). These studies suggest that monocytes/macrophages may
be contributing to CAA by releasing Aβ into the vessel walls following
apoptosis (Malm et al., 2010). Thus, ﬁnding a way to promote effective
Aβ clearance in these cells, while avoiding the activation of proinﬂam-
matory and neurotoxic pathways, should prove an attractive target for
AD therapies. In a recent study by Mizwicki and colleagues, the authors
treated peripheral blood mononuclear cells from AD patients with
1α,25-dihydroxyvitamin D3 (1,25D3), the active metabolite of vitamin
D, and resolvin D1 (RvD1), a derivative of omega-3 fatty acids, in an
effort to balance the activation of inﬂammation, speciﬁcally avoiding
neurotoxic pathways and promoting effective Aβ phagocytosis.
Their ﬁndings indicate that both 1,25D3 and RvD1 can enhance Aβ
phagocytosis, inhibit soluble Aβ-induced production of proinﬂammato-
ry cytokines and inhibit ﬁbrillar Aβ-induced apoptosis (Mizwicki et al.,
2013). These studies are promising, however, further investigation is
needed in order to determine whether such treatments will translate
into neuroprotection and/or cognitive improvement. It could also be
possible that AD patients exhibit enhanced levels of CCL2, which some
investigators believe could result in desensitization of cells and thus im-
pairment in their ability to inﬁltrate, respond to inﬂammatory or neuro-
nal insult, or phagocytose Aβ (Mildner et al., 2011; Naert and Rivest,
2013).
3.6. Concluding remarks
Taken together, these ﬁndings indicate that developing strategies to
stimulate the production of new and functioning peripheral monocytic
cells may prove an insightful avenue for further therapeutic develop-
ment (Fig. 1B). One such approach could involve genetically altering
these cells to express therapeutic genes (e.g., signals or neuroprotective
factors that help promote neuronal survival or Aβ clearance) and using
these cells to deliver therapeutic substances/capabilities to lesion sites
by exploiting their ability to home to regions of brain damage and Aβ
deposition. The selective migration of monocytes towards Aβ plaque
depositionmakes these cells optimal candidates for the delivery of ther-
apeutic substances to the AD brain.
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